Meriam Kabbaj
Chief Tech/Sci/R&D Officer at GENFIT
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Vincent Forster | M | - |
Versantis AG
 Versantis AG BiotechnologyHealth Technology Versantis AG develops liver disease therapeutics and diagnostics. Its pipeline include VS-01, a drug to support liver, brain, and kidneys; VS-02 and VS-03 that are solutions for chronic liver diseases and treatment of drug intoxications; and other products for the treatment of metabolic academia and diagnosis of hyperammonemia. The company was founded by Vincent Forster and Meriam Kabbaj in 2015 and is headquartered in Zurich, Switzerland. | 9 years |
| Jean-François Mouney | M | 68 | 25 years | |
| Stefanie Magner | F | 43 | 8 years | |
| Xavier Guille des Buttes | M | 82 | 18 years | |
| Laurent Lannoo | M | 54 | 16 years | |
| Jean-François Tiné | M | 67 | 3 years | |
| Pascal Caisey | M | 56 | 5 years | |
| Eric Baclet | M | 64 | 4 years | |
| Pascal Prigent | M | 56 | 6 years | |
| Katherine Kalin | F | 61 | 4 years | |
| Jean-Christophe Marcoux | M | 47 | 9 years | |
| Anne-Hélène Monsellato | F | 56 | 7 years | |
| Mark J. Fitzpatrick | M | 61 |
Versantis AG
Versantis AG BiotechnologyHealth Technology Versantis AG develops liver disease therapeutics and diagnostics. Its pipeline include VS-01, a drug to support liver, brain, and kidneys; VS-02 and VS-03 that are solutions for chronic liver diseases and treatment of drug intoxications; and other products for the treatment of metabolic academia and diagnosis of hyperammonemia. The company was founded by Vincent Forster and Meriam Kabbaj in 2015 and is headquartered in Zurich, Switzerland. | - |
| Catherine Larue | M | 68 | 7 years | |
| Dean Hum | M | 61 | 24 years | |
| Florence Séjourné | F | 52 | 25 years | |
| Christopher R. Seaton | M | - |
Versantis AG
Versantis AG BiotechnologyHealth Technology Versantis AG develops liver disease therapeutics and diagnostics. Its pipeline include VS-01, a drug to support liver, brain, and kidneys; VS-02 and VS-03 that are solutions for chronic liver diseases and treatment of drug intoxications; and other products for the treatment of metabolic academia and diagnosis of hyperammonemia. The company was founded by Vincent Forster and Meriam Kabbaj in 2015 and is headquartered in Zurich, Switzerland. | - |
| Michael Sidler | M | 55 |
Versantis AG
Versantis AG BiotechnologyHealth Technology Versantis AG develops liver disease therapeutics and diagnostics. Its pipeline include VS-01, a drug to support liver, brain, and kidneys; VS-02 and VS-03 that are solutions for chronic liver diseases and treatment of drug intoxications; and other products for the treatment of metabolic academia and diagnosis of hyperammonemia. The company was founded by Vincent Forster and Meriam Kabbaj in 2015 and is headquartered in Zurich, Switzerland. | - |
| Carol L. Addy | M | 64 | 5 years | |
| Peter Nicklin | M | 61 |
Versantis AG
Versantis AG BiotechnologyHealth Technology Versantis AG develops liver disease therapeutics and diagnostics. Its pipeline include VS-01, a drug to support liver, brain, and kidneys; VS-02 and VS-03 that are solutions for chronic liver diseases and treatment of drug intoxications; and other products for the treatment of metabolic academia and diagnosis of hyperammonemia. The company was founded by Vincent Forster and Meriam Kabbaj in 2015 and is headquartered in Zurich, Switzerland. | - |
| Robert Schier | M | - |
Versantis AG
Versantis AG BiotechnologyHealth Technology Versantis AG develops liver disease therapeutics and diagnostics. Its pipeline include VS-01, a drug to support liver, brain, and kidneys; VS-02 and VS-03 that are solutions for chronic liver diseases and treatment of drug intoxications; and other products for the treatment of metabolic academia and diagnosis of hyperammonemia. The company was founded by Vincent Forster and Meriam Kabbaj in 2015 and is headquartered in Zurich, Switzerland. | - |
| Thomas Baetz | M | 50 | 3 years | |
| John Brozek | M | 47 | - | |
| Émilie Desodt | F | 41 | 6 years | |
| Stephanie Boyer | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jean-Christophe Leroux | M | - |
Versantis AG
Versantis AG BiotechnologyHealth Technology Versantis AG develops liver disease therapeutics and diagnostics. Its pipeline include VS-01, a drug to support liver, brain, and kidneys; VS-02 and VS-03 that are solutions for chronic liver diseases and treatment of drug intoxications; and other products for the treatment of metabolic academia and diagnosis of hyperammonemia. The company was founded by Vincent Forster and Meriam Kabbaj in 2015 and is headquartered in Zurich, Switzerland. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 19 | 73.08% |
| Switzerland | 7 | 26.92% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Meriam Kabbaj
- Personal Network
